JP2023500248A5 - - Google Patents
Info
- Publication number
- JP2023500248A5 JP2023500248A5 JP2022525129A JP2022525129A JP2023500248A5 JP 2023500248 A5 JP2023500248 A5 JP 2023500248A5 JP 2022525129 A JP2022525129 A JP 2022525129A JP 2022525129 A JP2022525129 A JP 2022525129A JP 2023500248 A5 JP2023500248 A5 JP 2023500248A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- epitope
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2019-0142251 | 2019-11-08 | ||
| KR20190142251 | 2019-11-08 | ||
| PCT/KR2020/015656 WO2021091359A1 (ko) | 2019-11-08 | 2020-11-09 | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500248A JP2023500248A (ja) | 2023-01-05 |
| JP2023500248A5 true JP2023500248A5 (https=) | 2023-11-16 |
Family
ID=75848106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525129A Pending JP2023500248A (ja) | 2019-11-08 | 2020-11-09 | 制御性ｔ細胞表面抗原のエピトープおよびこれに特異的に結合する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250243272A1 (https=) |
| EP (1) | EP4056586A4 (https=) |
| JP (1) | JP2023500248A (https=) |
| KR (1) | KR102488967B1 (https=) |
| CN (1) | CN114929733A (https=) |
| AU (1) | AU2020380072B2 (https=) |
| BR (1) | BR112022008730A2 (https=) |
| CA (1) | CA3156600A1 (https=) |
| WO (1) | WO2021091359A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102302393B1 (ko) * | 2018-10-17 | 2021-09-16 | 주식회사 굳티셀 | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 |
| CN117716238A (zh) * | 2021-07-16 | 2024-03-15 | 古德T细胞有限公司 | 调节性t细胞表面抗原的表位及其特异性结合的抗体 |
| US20250018033A1 (en) * | 2021-11-24 | 2025-01-16 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
| KR20240115192A (ko) * | 2023-01-17 | 2024-07-25 | 주식회사 굳티셀 | 조절 t 세포 표면 항원 및 이에 특이적으로 결합하는 항체 |
| CN120882739A (zh) * | 2023-03-10 | 2025-10-31 | 古德T细胞有限公司 | 调节性t细胞表面抗原的表位，以及特异性结合该表位的抗体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011066048A1 (en) * | 2009-10-22 | 2011-06-03 | Thomas Jefferson University | Cell-based anti-cancer compositions and methods of making and using the same |
| KR101847523B1 (ko) * | 2011-01-24 | 2018-05-28 | 연세대학교 산학협력단 | 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 |
| DE102016123859B3 (de) * | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| KR20180116925A (ko) * | 2017-04-18 | 2018-10-26 | 주식회사 굳티셀 | 암 또는 면역 질환의 예방 또는 치료용 약학 조성물 |
| KR20180116924A (ko) * | 2017-04-18 | 2018-10-26 | 주식회사 굳티셀 | 면역 세포 표면 단백질의 항원 결정기인 폴리펩티드 |
| CN110799534B (zh) * | 2017-04-18 | 2023-05-12 | 古德T细胞有限公司 | Lrig-1蛋白的特异性结合分子及其用途 |
| EP3755350A4 (en) * | 2018-02-23 | 2021-11-03 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER |
| KR101959237B1 (ko) * | 2018-02-26 | 2019-03-20 | 주식회사 굳티셀 | 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 |
| KR102194644B1 (ko) * | 2018-04-26 | 2020-12-24 | 주식회사 굳티셀 | 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
-
2020
- 2020-11-09 US US17/758,550 patent/US20250243272A1/en not_active Abandoned
- 2020-11-09 WO PCT/KR2020/015656 patent/WO2021091359A1/ko not_active Ceased
- 2020-11-09 CA CA3156600A patent/CA3156600A1/en active Pending
- 2020-11-09 AU AU2020380072A patent/AU2020380072B2/en active Active
- 2020-11-09 KR KR1020200148886A patent/KR102488967B1/ko active Active
- 2020-11-09 EP EP20885858.9A patent/EP4056586A4/en active Pending
- 2020-11-09 CN CN202080077856.2A patent/CN114929733A/zh active Pending
- 2020-11-09 JP JP2022525129A patent/JP2023500248A/ja active Pending
- 2020-11-09 BR BR112022008730A patent/BR112022008730A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500248A5 (https=) | ||
| KR101287280B1 (ko) | 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제 | |
| CN100424175C (zh) | ErbB-3 用于肿瘤治疗的方法和组合物 | |
| JP2022502371A5 (https=) | ||
| CN110740754A (zh) | 一种抗间皮素抗体及其抗体药物缀合物 | |
| JP2022527635A5 (https=) | ||
| JP2022169589A5 (https=) | ||
| JP2020519295A5 (https=) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| US20230174660A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| JP2023040169A5 (https=) | ||
| JP2023538422A5 (https=) | ||
| JP2014528714A5 (https=) | ||
| JP6936399B2 (ja) | 抗ｓｅｚ６抗体薬物コンジュゲート及び使用方法 | |
| JP2020521478A5 (https=) | ||
| CN101663317A (zh) | 胰高血糖素样蛋白-1受体glp-1r激动剂化合物 | |
| US20170247465A1 (en) | Combination therapy for treatment of cancer | |
| JP2020509737A5 (https=) | ||
| JP2017043620A (ja) | 溶解性ペプチド−Ｈｅｒ２／ｎｅｕ（ヒト上皮成長因子レセプター２）リガンド結合体およびその使用方法 | |
| HRP20161449T1 (hr) | Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena | |
| JPS63503144A (ja) | 葉酸類縁体のアミン誘導体 | |
| TW201739472A (zh) | 抗磷脂醯肌醇蛋白聚糖-3抗體及妥布賴森(tubulysin)類似物之抗體藥物結合物、製備及用途 | |
| JP2024519904A5 (https=) | ||
| DK0866861T3 (da) | Molekylær kloning og karakterisering af molekyler forbundet med relaxin og ligandinsulinfamilien | |
| JP2024516392A5 (https=) |